Drug intelligence / Profile preview

DCOY101

Development stage: Preclinical
Lead developer: Decoy Therapeutics
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides

Overview

DCOY101 is a peptide conjugate drug candidate developed by Decoy Therapeutics. It is part of Decoy's AI-driven IMP 3 ACT platform and is being developed for the treatment of infectious diseases and oncology.

Beyond the preview

Go deeper on DCOY101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DCOY101.

Explore the full profile